• Pyxis Oncology posted a wider net loss of $23.27 million for three months ended March 31, 2026, versus $21.16 million a year earlier.
• Research and development expense rose 17.24% to $19.98 million, driven by higher MICVO program costs; general and administrative expense fell 25.43% to $4.38 million.
• Other income, net dropped 38.04% to $1.09 million on lower interest and investment income, partly offset by higher sublease income.
• Cash, cash equivalents and marketable debt securities totaled $41 million at March 31, 2026; net cash used in operating activities increased to $26 million from $22.54 million.
• Completed target enrollment of about 40 patients in MICVO Phase 1 monotherapy dose expansion in first quarter; expects updated monotherapy data mid-2026 and combination data in second half of 2026, while guiding cash runway into fourth quarter of 2026 and flagging substantial doubt about going concern over next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-222843), on May 14, 2026, and is solely responsible for the information contained therein.